JP2022543070A - 多価及び多重特異性ナノ粒子プラットフォーム及び方法 - Google Patents

多価及び多重特異性ナノ粒子プラットフォーム及び方法 Download PDF

Info

Publication number
JP2022543070A
JP2022543070A JP2022506525A JP2022506525A JP2022543070A JP 2022543070 A JP2022543070 A JP 2022543070A JP 2022506525 A JP2022506525 A JP 2022506525A JP 2022506525 A JP2022506525 A JP 2022506525A JP 2022543070 A JP2022543070 A JP 2022543070A
Authority
JP
Japan
Prior art keywords
nanocage
fusion protein
fragment
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543070A5 (cg-RX-API-DMAC7.html
Inventor
- フィリップ ジュリアン、ジャン
ディアス、エデュルネ ルハス
トレアノール、ベッビン
ザオ、チャンチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
University of Toronto
Original Assignee
Hospital for Sick Children
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children, University of Toronto filed Critical Hospital for Sick Children
Publication of JP2022543070A publication Critical patent/JP2022543070A/ja
Publication of JP2022543070A5 publication Critical patent/JP2022543070A5/ja
Priority to JP2025154827A priority Critical patent/JP2026004351A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
JP2022506525A 2019-08-01 2020-07-31 多価及び多重特異性ナノ粒子プラットフォーム及び方法 Pending JP2022543070A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154827A JP2026004351A (ja) 2019-08-01 2025-09-18 多価及び多重特異性ナノ粒子プラットフォーム及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881899P 2019-08-01 2019-08-01
US62/881,899 2019-08-01
PCT/CA2020/051061 WO2021016724A1 (en) 2019-08-01 2020-07-31 Multi-valent and multi-specific nanoparticle platforms and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154827A Division JP2026004351A (ja) 2019-08-01 2025-09-18 多価及び多重特異性ナノ粒子プラットフォーム及び方法

Publications (2)

Publication Number Publication Date
JP2022543070A true JP2022543070A (ja) 2022-10-07
JP2022543070A5 JP2022543070A5 (cg-RX-API-DMAC7.html) 2023-08-08

Family

ID=74228187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506525A Pending JP2022543070A (ja) 2019-08-01 2020-07-31 多価及び多重特異性ナノ粒子プラットフォーム及び方法
JP2025154827A Pending JP2026004351A (ja) 2019-08-01 2025-09-18 多価及び多重特異性ナノ粒子プラットフォーム及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154827A Pending JP2026004351A (ja) 2019-08-01 2025-09-18 多価及び多重特異性ナノ粒子プラットフォーム及び方法

Country Status (10)

Country Link
US (1) US20230145060A1 (cg-RX-API-DMAC7.html)
EP (1) EP4007779A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022543070A (cg-RX-API-DMAC7.html)
KR (1) KR20220107151A (cg-RX-API-DMAC7.html)
CN (3) CN121203033A (cg-RX-API-DMAC7.html)
AU (1) AU2020320459A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001800A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149320A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001387A (cg-RX-API-DMAC7.html)
WO (1) WO2021016724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220411508A1 (en) * 2019-09-09 2022-12-29 The Regents Of The University Of California Compositions and methods for making and using multispecific antibodies
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
EP4370558A4 (en) * 2021-07-12 2025-09-10 Hospital For Sick Children OPTIMIZED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS
MX2024003140A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Construcciones, composiciones y metodos de multabody optimizados.
MX2024003139A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Multabody dirigido a dr5 para el tratamiento del cancer.
EP4416189A4 (en) * 2021-10-16 2025-08-27 Hospital For Sick Children MODIFIED MULTIBODY CONSTRUCTS, COMPOSITIONS AND METHODS TARGETING SARS-CoV-2
US20250002564A1 (en) * 2021-10-16 2025-01-02 The Hospital For Sick Children Modified multabody constructs, compositions, and methods
CN116804062A (zh) * 2022-03-23 2023-09-26 昆山新蕴达生物科技有限公司 一种FcRn结合纳米颗粒及其用途
CN119968382A (zh) * 2022-09-27 2025-05-09 科力博株式会社 包含主氨基酸由带电和极性氨基酸组成的肽标签并形成自组装体的融合蛋白及使用其纯化重组蛋白的方法
WO2024071970A1 (ko) * 2022-09-27 2024-04-04 크리포 주식회사 주요 아미노산이 전하성 아미노산으로 구성된 펩타이드 태그를 포함하여 자가 조립체를 형성하는 융합 단백질 및 이를 이용하여 재조합 단백질을 정제하는 방법
KR102946895B1 (ko) * 2022-10-21 2026-04-02 충남대학교산학협력단 SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도
WO2024099273A1 (zh) * 2022-11-07 2024-05-16 厦门大学 一种融合蛋白以及包含其的颗粒化的抗原
EP4634238A1 (en) * 2022-12-18 2025-10-22 Radiant Biotherapeutics Inc. Multivalent hematopoietic cell engagers or activators
AU2023407259A1 (en) * 2022-12-18 2025-06-26 Radiant Biotherapeutics Inc. Multivalent and multispecific cytokine antagonists
CN115819626B (zh) * 2022-12-23 2026-04-28 北京吉诺卫生物科技有限公司 重组铁蛋白纳米颗粒及其制备方法
CN121127490A (zh) * 2022-12-28 2025-12-12 生物技术欧洲股份公司 靶向hiv的rna组合物
WO2024254514A1 (en) * 2023-06-08 2024-12-12 The University Of North Carolina At Chapel Hill Engineered antibody fusion proteins with modulable binding constants and their applications
CN116715780A (zh) * 2023-06-09 2023-09-08 中国人民解放军陆军军医大学 重组铜绿假单胞菌纳米颗粒蛋白及其制备方法和应用
WO2025054730A1 (en) * 2023-09-13 2025-03-20 The Hospital For Sick Children Hiv-1-targeted multabody constructs, compositions, and methods
WO2026003586A2 (en) * 2024-06-27 2026-01-02 Popvax Private Limited Multisubunit herpesvirus vaccines and therapeutics
WO2026092903A1 (en) 2024-10-29 2026-05-07 Albert-Ludwigs-Universität Freiburg Körperschaft Des Öffentlichen Rechts Encapsulation of dimer or tandem-enzymes within capsid proteins, in particular within engineered encapsulins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016122259A1 (ko) * 2015-01-30 2016-08-04 동국대학교 산학협력단 단일사슬항체조각과 페리틴을 포함하는 융합단백질 및 그의 용도
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097841B2 (en) * 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016122259A1 (ko) * 2015-01-30 2016-08-04 동국대학교 산학협력단 단일사슬항체조각과 페리틴을 포함하는 융합단백질 및 그의 용도
WO2019023811A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATURE BIOTECHNOLOGY, vol. 28, no. 2, JPN6024024896, 2010, pages 157 - 159, ISSN: 0005460173 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 33, JPN6024024897, 2006, pages 23514 - 23524, ISSN: 0005460172 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 292, no. 9, JPN6024024895, 2017, pages 3900 - 3908, ISSN: 0005460174 *

Also Published As

Publication number Publication date
CN114867754A (zh) 2022-08-05
CA3149320A1 (en) 2021-02-04
EP4007779A4 (en) 2023-09-06
JP2026004351A (ja) 2026-01-14
KR20220107151A (ko) 2022-08-02
CN121449754A (zh) 2026-02-03
BR112022001800A2 (pt) 2022-04-12
MX2022001387A (es) 2022-06-08
US20230145060A1 (en) 2023-05-11
WO2021016724A1 (en) 2021-02-04
EP4007779A1 (en) 2022-06-08
CN121203033A (zh) 2025-12-26
AU2020320459A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
JP2026004351A (ja) 多価及び多重特異性ナノ粒子プラットフォーム及び方法
US20250114475A1 (en) Nanoparticle platform for antibody and vaccine delivery
ES2911752T3 (es) Anticuerpos contra CD40
US20240317842A1 (en) Multabody constructs, compositions, and methods
US20230372461A1 (en) Immunogenic peptides, compositions, and methods for the treatment and/or prevention of malaria
US20240182544A1 (en) Polypeptides targeting dr4 and/or dr5 and related compositions and methods
RU2858491C2 (ru) Мультивалентные и мультиспецифические платформы наночастиц и способы
WO2019023812A1 (en) VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
HK40082289A (en) Nanoparticle platform for antibody and vaccine delivery
CN116615255A (zh) 靶向SARS-CoV-2的多肽及相关组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250918